One physician asked the cardiologists directly where things stand on aspirin for everyone with elevated Lp(a). The first answer: give an antiplatelet (clopidogrel rather than aspirin) if there is plaque on CT or carotid ultrasound, and nothing if there is not.
Another cardiologist put it in risk-benefit terms: you need evidence of significant cardiovascular disease to make the benefit outweigh the bleeding risk. A third separated the guideline answer from the practical one: treat any evidence of atherosclerosis, especially if accelerated, and weigh monogenic and polygenic risk, since isoform size and plasma level drive the damage.
The case for aspirin in high-Lp(a) patients rests on genotype-subgroup analyses rather than a trial built for the question. A Women's Health Study analysis and a 2022 ASPREE genotype analysis in JACC both found benefit in carriers of Lp(a)-raising variants, at the cost of bleeding. The broad primary-prevention trials (ASPREE, ARRIVE, ASCEND) were neutral or harmful in unselected patients, and guidelines treat elevated Lp(a) as a risk-enhancing factor, not a standalone indication.
The structural point underneath: there is still no approved therapy that lowers Lp(a) itself, with several agents in phase 3. Until they read out, aspirin and aggressive control of every other risk factor are the levers available.
Key takeaways
- Aspirin for elevated Lp(a) is a targeted decision, not a blanket one.
- Reach for it with subclinical atherosclerosis on imaging or a genuinely high genetic burden.
- Weigh bleeding risk explicitly in every patient.
- In an asymptomatic patient with only a high number, the trial you would want does not exist yet.
From Buzz in the chat, the longevitydocs™ Sunday newsletter, July 19, 2026. Member discussion, not clinical guidance.
Originally published in The Longevity Medicine Intelligence newsletter.
